Inflammatory responses predict long-term mortality risk in community-acquired pneumonia

European Respiratory Journal

Volumn 37, Issue 6, 2011, Pages 1439-1446

  Guertler, C ^a   Wirz, B ^a   Christ Crain, M ^a   Zimmerli, W ^b   Mueller, B ^c   Schuetz, P ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Liestal ^*  (Switzerland)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Long term follow up; Mortality; Pneumonia; Respiratory tract infection

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CHILLS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; FEVER; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASMS; PNEUMONIA; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 79958003426     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00121510     Document Type: Article

References (37)

1. Menendez R, Torres A, Zalacain R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59: 960-965. (Pubitemid 39490781)
2. Almirall J, Bolibar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15: 757-763. (Pubitemid 30196306)
3. Macfarlane J, Lewis SA, Macfarlane R, et al. Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the UK: implications for developing management guidelines. Respir Med 1997; 91: 427-434. (Pubitemid 27308197)
4. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754. (Pubitemid 32578779)
5. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250. (Pubitemid 27044625)
6. Struck J, Tao C, Morgenthaler NG, et al. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004; 25: 1369-1372. (Pubitemid 39180069)
7. Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9: R816-R824.
8. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96.
9. Schuetz P, Christ-Crain M, Morgenthaler NG, et al. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007; 14: 345-351.
10. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136: 823-831.
11. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14: R106.
12. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52: 48-58.
13. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-2602. (Pubitemid 44413058)
14. Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28: 55-60.
15. Schuetz P, Suter-Widmer I, Chaudri A, et al. Prognostic value of procalcitonin in community-aquired pneumonia. Eur Respir J 2011; 37: 384-392.
16. Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008; 87: 329-334.
17. Yende S, Tuomanen EI, Wunderink R, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med 2005; 172: 1440-1446. (Pubitemid 43069818)
18. Brancati FL, Chow JW, Wagener MM, et al. Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet 1993; 342: 30-33. (Pubitemid 23183921)
19. Mortensen EM, Kapoor WN, Chang CC, et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37: 1617-1624. (Pubitemid 37549947)
20. Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010; 38: 1276-1283.
21. Koivula I, Sten M, Makela PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999; 159: 1550-1555. (Pubitemid 29340308)
22. Hedlund JU, Ortqvist AB, Kalin ME, et al. Factors of importance for the long term prognosis after hospital treated pneumonia. Thorax 1993; 48: 785-789. (Pubitemid 23244338)
23. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169: 910-914. (Pubitemid 38457316)
24. Schuetz P, Christ-Crain M, Wolbers M, et al. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007; 7: 102.
25. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059-1066.
26. Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995; 51: 1469-1482. (Pubitemid 26030191)
27. El Solh A, Pineda L, Bouquin P, et al. Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatr 2006; 6: 12.
28. Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004; 125: 1335-1342. (Pubitemid 38501347)
29. Menendez R, Martinez R, Reyes S, et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009; 64: 987-992.
30. Seligman R, Meisner M, Lisboa TC, et al. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006; 10: R125.
31. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007; 7: 10.
32. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453-1459. (Pubitemid 27300393)
33. Reade MC, Yende S, D'Angelo G, et al. Differences in immune response may explain lower survival among older men with pneumonia. Crit Care Med 2009; 37: 1655-1662.
34. Baune BT, Rothermundt M, Ladwig KH, et al. Systemic inflammation (interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study. Age (Dordr) 2010; [Epub ahead of print DOI: 10.1007/s11357-010-9165-5].
35. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51: 1823-1829. (Pubitemid 41368172)
36. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001; 22: 1693-1711. (Pubitemid 34062786)
37. Tenenbaum A, Fisman EZ. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010; 9: 24.